At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 123 enrolled
Drug / intervention
Lenvatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Trial to Assess the Efficacy of Lenvatinib in Metastatic Neuroendocrine Tumors. (TALENT STUDY)
In Brief
A Phase 2 clinical trial evaluating Lenvatinib for Neuroendocrine Tumors. Completed, enrolled 123 participants across 22 sites in 4 countries.
Detailed Summary
This is a prospective, international, multi-center, open label, stratified, exploratory phase II study evaluating the efficacy and safety of lenvatinib in patients with advanced/metastatic, neuroendocrine tumors of the pancreas after progression to a previous targeted agent (cohort A) or gastrointestinal tract after progression to somatostatin analogues (cohort B).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Tumors
CountriesAustria, Italy, Spain, United Kingdom
CollaboratorsEisai Limited, Experior S.L.
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
First PostedFeb 2016
Primary CompletionDec 2017
Study CompletionAug 2020
TodayJul 2026
First PostedFeb 10, 2016
Enrollment StartOct 1, 2015
Primary CompletionDec 1, 2017
Study CompletionAug 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.4 years ago
Interventions
Lenvatinibdrug